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Abstract
It has been clearly established that mitogen-activated protein kinases (MAPKS) are important mediators of angiotensin II
(Ang II) signaling via AT1 receptors in the vasculature. However, evidence for a role of these kinases in changes of Ang II-
induced vasoconstriction in obesity is still lacking. Here we sought to determine whether vascular MAPKs are differentially
activated by Ang II in obese animals. The role of AT2 receptors was also evaluated. Male monosodium glutamate-induced
obese (obese) and non-obese Wistar rats (control) were used. The circulating concentrations of Ang I and Ang II, determined
by HPLC, were increased in obese rats. Ang II-induced isometric contraction was decreased in endothelium-intact resistance
mesenteric arteries from obese compared with control rats and exhibited a retarded AT1 receptor antagonist response.
Blocking of AT2 receptors and inhibition of either endothelial nitric oxide synthase (eNOS) or extracellular signal-regulated
protein kinases 1 and 2 (ERK1/2) restored Ang II-induced contraction in obese rats. Western blot analysis revealed increased
protein expression of AT2 receptors in arteries from obese rats. Basal and Ang II-induced ERK1/2 phosphorylation was also
increased in obese rats. Blockade of either AT1 or AT2 receptors corrected the increased ERK1/2 phosphorylation in arteries
from obese rats to levels observed in control preparations. Phosphorylation of eNOS was increased in obese rats. Incubation
with the ERK1/2 inhibitor before Ang II stimulation did not affect eNOS phosphorylation in control rats; however, it
corrected the increased phosphorylation of eNOS in obese rats. These results clearly demonstrate that enhanced AT2
receptor and ERK1/2-induced, NO-mediated vasodilation reduces Ang II-induced contraction in an endothelium-dependent
manner in obese rats.
Citation: Hagihara GN, Lobato NS, Filgueira FP, Akamine EH, Araga˜o DS, et al. (2014) Upregulation of ERK1/2-eNOS via AT2 Receptors Decreases the Contractile
Response to Angiotensin II in Resistance Mesenteric Arteries from Obese Rats. PLoS ONE 9(8): e106029. doi:10.1371/journal.pone.0106029
Editor: Michael Bader, Max-Delbru¨ck Center for Molecular Medicine (MDC), Germany
Received April 27, 2014; Accepted July 28, 2014; Published August 29, 2014
Copyright:  2014 Hagihara et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All data are included within the paper.
Funding: This work was supported by grants from Fundac¸a˜o de Amparo a Pesquisa do Estado de Sa˜o Paulo - FAPESP [2007/58311-0, 2008/51622-3 and 2010/
03642-5], Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico (CNPq) - INCT Obesity and Diabetes and individual research grants to MHCC and ZBF -,
and Coordenac¸a˜o de Aperfeic¸oamento de Pessoal de Nı´vel Superior (CAPES) Brazil. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: zbfortes@icb.usp.br
Introduction
Angiotensin II (Ang II), the effector peptide of the renin-
angiotensin system (RAS), is a vasoactive peptide that exerts a
variety of vascular actions through activation of at least two
different types of G protein–coupled receptors, the type 1 receptor
(AT1) and the type 2 receptor (AT2) [1–3]. Binding of Ang II to
the AT1 receptor activates a myriad of signaling pathways, among
them the mitogen-activated protein kinases (MAPKS), a family of
serine/threonine kinases which are classically associated with
vascular smooth muscle cell contraction, migration, adhesion,
collagen deposition, cell growth, differentiation, and survival. Of
the main MAPKs, extracellular signal-regulated kinases (ERK1/
2), p38 MAPK, and stress-activated protein kinase/c-Jun N-
terminal kinases (SAPK/JNK) are the best characterized [4–9].
Although Ang II signaling via AT1 receptor has been
extensively characterized, Ang II signaling via AT2 receptors is
still not completely understood. In small resistance vessels,
activation of AT1 receptors promotes vasoconstriction and smooth
muscle proliferation [10], whereas AT2 receptor stimulation
activates an autacoids vasodilator cascade composed of bradykinin
(BK), nitric oxide (NO), and guanosine cyclic 3, 5 -monophos-
phate (cGMP) that mediates vasodilation, counteracting AT1
receptor-induced contraction and providing a protective role
[11,12]. Indeed, AT2 receptor knockout mice have higher blood
pressure and an exaggerated response to Ang II infusion on blood
pressure [13]. Furthermore, AT2 receptor is upregulated in
certain pathological conditions such as hypertension, vascular
injury, and inflammation [14,15]. The significance of AT2
receptor in the establishment of vascular dysfunction in obesity,
however, is not defined.
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Recent studies have demonstrated that Ang II plays an
important role in obesity by promoting changes in energetic
homeostasis and vascular function [16–17]. Increased activation of
MAPKs has also been described to be involved is changes of the
energy metabolism in obesity [18–20]. Moreover, it is now clearly
established that MAPKs are important mediators of Ang II effects
in the vasculature, including vascular smooth muscle cells
differentiation, proliferation, migration, and fibrosis [21,22].
However, evidence for a direct role of these kinases in changes
of the vascular reactivity to Ang II in obesity is still lacking. Here
we sought to determine whether MAPKs activation, in particular
ERK1/2, p38 MAPK, and JNK, are differentially regulated by
Ang II in vessels from obese animals. The role of AT2 receptors
was also evaluated. To address these issues, we used resistance
mesenteric arteries from male monosodium glutamate (MSG)-
induced obese rat, a model of obesity with insulin resistance and
dyslipidemia that may occur without the presence of type II
diabetes or hypertension depending on the age at which the
animals are studied [23], making them a relevant model to
investigate the vascular dysfunction associated with obesity. Our
results showed that activation SAPK/JNK and p38MAPK
pathways contribute to the maintenance of vasoconstriction to
Ang II via AT1 receptors while activation of ERK1/2-eNOS
pathway via AT2 receptors in the endothelium contributes to
counteracting contraction and decrease the response to Ang II in
this experimental model of obesity.
Methods
Animals, Induction and Characterization of Obesity
All animal procedures were approved by the Ethical Committee
for Animal Research of the Institute of Biomedical Sciences,
University of Sao Paulo, conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised 1996).
Male Wistar rats received subcutaneous injections of MSG (4.0 g/
kg) dissolved in 0.9% NaCl (obese rats) or an equivalent volume of
vehicle (control rats), from the second to sixth day after birth. The
breeding conditions were followed as previously described [23]. All
experimental groups were studied at 16 weeks of age. The water
and food consumption was determined by placing the rats in
metabolic cages. Rats were acclimated for 72 h and data were
collected over the next 24 h.
On the day of the experiment, after food deprivation (5 h),
obese and control rats were weighed, and blood samples were
taken from the descending aorta under sodium thiopental
anesthesia (50 mg/kg, intraperitoneally, Crista´lia, Brazil), for
biochemical parameters assessment. Glucose levels and the lipid
profile were assessed spectrophotometrically using colorimetric
method (Celm, Brazil). Insulin was determined by radioimmuno-
assay (Linco, USA). The Homeostasis Model Assessment (HOMA-
IR), an index of insulin resistance, was calculated from glucose and
insulin levels, using the equation: fasting insulin (mIU/mL) 6
fasting glucose (mmol/L)/22.5 [24]. Lee’s obesity index was
calculated as follows: body weight1/3(g)/nasal-anal length
(cm)x100. The white adipose tissue (epididymal and retroperito-
neal) as well as gastrocnemius and long digital extensor muscles
were weighted.
The blood pressure (BP) was measured in unanesthetized
animals by indirect tail-cuff method (PowerLab 4/S, ADInstru-
ments, Australia). Rats were maintained at 37uC for 10 min, and
then three consecutive stable BP measurements were averaged.
Plasma Concentrations of Angiotensin Metabolites by
HPLC
Angiotensin peptide measurements were performed as de-
scribed in detail previously [25–27]. A cocktail of protease
inhibitors containing 1 mmol/l p-hydroxy-mercury benzoate,
30 mmol/l o-phenanthroline, 1 mmol/l PMSF and 1 mmol/l
pepstatin A (140 ml per 1 ml of blood) was added to the blood
samples; this mixture was then centrifuged at 1500 g at 4uC for
20 min and stored at 280uC until further analysis.
The plasma samples were concentrated in a C18 Sep-Pak
column activated with sequential washes with methanol (5 ml),
tetrahydrofuran (5 ml), hexane (5 ml), methanol (5 ml) and water
(10 ml). The peptides were eluted with an ethanol/acetic acid/
water (45:2:3) mix. The elutions were then freeze-dried and
resuspended in 500 ml of mobile phase A [5% acetronitrile (50 ml)
in 0.1% orthophosphoric acid (1 ml)]. The peptide was separated
on a reverse-phase column [Aquapore ODS 300 (250 mm6
4.6 mm)] using a gradient of 5–35% of mobile phase B (95%
acetonitrile in 0.1% H3PO4) with a flow of 1.5 ml/min for 40 min
in a Milton Roy System (containing two constaMetric 3000
pumps, a UV detector spectroMonitor 3100, a programmer GM
4000 and a mixer). Synthetic standards were used and peptide
detection was carried out at 214 nm. The results are expressed in
ng/ml.
Vascular Function Studies
Force development in response to a specific experimental
protocol was evaluated in mesenteric arteries from both groups as
previously described [28]. The mesenteric vascular bed was
removed and placed in modified Krebs-Henseleit solution of the
following composition (in mM): 130 NaCl, 14.9 NaHCO3, 4.7
KCl, 1.18 KH2PO4, 1.17 MgSO4?7H2O, 5.5 glucose, 1.56
CaCl2?2H2O, and 0.026 EDTA. Segments (2 mm in length) of
the mesenteric arteries were mounted on 40- mm wires in a small
vessel myograph for isometric tension recording. The vessels were
allowed to equilibrate for about 30 min in modified Krebs-
Henseleit solution, which was gassed with 5% CO2 in O2 to
maintain a pH of 7.4. The relationship between resting wall
tension and internal circumference was determined, and the
internal circumference, L100, corresponding to a transmural
pressure of 100 mmHg for a relaxed vessel in situ, was calculated.
The vessels were set to the internal circumference L1, given by
L1= 0.9xL100. The effective internal lumen diameter was
determined as L1=L1/p, and was between 200 and 300 mm.
After stabilization, arterial integrity was assessed by stimulation of
vessels with 120 mM KCl. Endothelial function was assessed by
testing the relaxant effect of acetylcholine (ACh, 1 mM) on vessels
precontracted with phenylephrine (1 mM). The failure of ACh to
elicit relaxation of mesenteric arteries (which were previously
subjected to rubbing of the intimal surface with a human hair) was
taken as proof of endothelium removal.
Experimental Protocols
Non-cumulative concentration–response curves to Ang II were
performed in different segments of mesenteric arteries. The curves
were performed on a top of a submaximal tone (30 to 40% of the
maximum response) induced by norepinephrine (NE) to avoid
rapid receptor desensitization in the mesenteric arteries that would
diminish contraction to Ang II [29]. To determine whether the
alterations of Ang II-evoked responses were receptor specific,
cumulative concentration–effect curves induced by the adrenergic
agonist NE were also obtained. To investigate if the contractile
responses were dependent on the intact endothelium, responses
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were also assessed in endothelium-denuded arteries. The contrac-
tile responses to Ang II and NE were normalized by expressing
them as the percentage of contraction relative to contractions
induced by KCl in a concentration that produces almost
maximum contraction (120 mM).
The role of specific Ang II receptors in the Ang II-induced
responses was assessed in the presence of the AT1 receptor
antagonist losartan (incubated at the concentrations of 0.3 mM and
10 mM) or the AT2 receptor antagonist PD 123319 (1 mM). In
order to investigate the contribution of NO in the vascular effects
of Ang II, mesenteric arteries were pretreated with Nv-nitro-L-
arginine methyl ester (L-NAME, 100 mM), a NO synthase
inhibitor. To determine the involvement of MAPKs on Ang II-
induced contraction, concentration-effect curves to Ang II and NE
were performed either in the absence (control) or in the presence
of PD98059 (1 mM), a specific MEK/ERK1/2 inhibitor,
SB203580 (1 mM), a catalytic inhibitor for p38 MAPK, or
SP600125 (1 mM), an inhibitor of JNK. To elucidate the
contribution of reactive oxygen species (ROS) in the vascular
effects of Ang II, mesenteric arteries were pretreated with
apocynin (100 mM), a NADPH inhibitor. Each preparation was
tested with a single inhibitor and tissues were incubated with these
agents for 30 minutes prior to the concentration-response curves.
Western Blotting
Mesenteric arteries from control and obese rats were stimulated
with Ang II (0.1 mmol/L) or vehicle for 10 min in the absence or
in the presence of the AT1 receptor antagonist losartan (10 mM),
the AT2 receptor antagonist PD123319 (1 mM), or the ERK1/2
inhibitor PD98059 (1 mM).
After the incubation protocols, vessels were frozen in liquid
nitrogen and proteins were extracted (50 mg) and separated by
electrophoresis on 10% polyacrylamide gels and transferred to
nitrocellulose membranes. Nonspecific binding sites were blocked
with 5% skim milk in Tris-buffered saline solution with Tween
(0.1%) for 1 hour at 24uC. Membranes were incubated with
antibodies (at the indicated dilutions) overnight at 4uC. Antibodies
were as follows: anti-p38MAPK (Thr180/Tyr182), anti-ERK1/2
(Thr202/Tyr204), anti-SAPK/JNK (Thr183/Tyr185), anti-AT1,
anti-AT2, anti-eNOs (1:500, Cell Signaling), anti-phospho eNOs
(1:1000, Cell Signaling), and anti-a-actin (1:20000, Sigma). After
incubation with secondary antibodies, signals were revealed by
chemiluminescence, visualized by autoradiography and quantified
densitometrically. Results were normalized to a-actin expression
and expressed as units relative to the control.
Data Analysis and Statistical Procedures
The contractile responses are expressed as percentage of the
response to KCl. The individual cumulative concentration-
response curves to NE were fitted into a curve by non-linear
regression analysis. pEC50 (defined as the negative logarithm of
the EC50 values) and maximal response were compared by t-tests
or ANOVA, when appropriated. The non-cumulative concentra-
tion-response curves to Ang II were compared by two way
ANOVA. The Prism software, version 5.0 (GraphPad Software
Inc., San Diego, CA, USA) was used to perform the analysis of
these parameters as well as to fit the sigmoidal curves. Data are
presented as mean 6 SEM. N represents the number of animals
used. P values less than 0.05 were considered significant.
Drugs
Sodium thiopental was purchased from Crista´lia LTDA (Sa˜o
Paulo, Brazil). Acetylcholine, angiotensin II, apocynin, losartan,
PD98059, SB203580, SP600125, PD123319, monosodium gluta-
mate, norepinephrine and Nv-nitro-L-arginine methyl ester were
purchased from Sigma Chemical Co (St. Louis, MO).
Results
General Characteristics of Monosodium
Glutamate-Induced Obese Rats
General and biochemical characteristics of control and obese
rats are depicted in Table 1. Sixteen-week-old obese rats displayed
higher Lee index, fat mass, serum triglycerides and low density
lipoprotein (LDL) cholesterol. In addition, enhanced HOMA-IR
index and hyperinsulinemia were found in obese rats. No
difference in BP levels was found between the groups.
Plasma measurements of angiotensin metabolites revealed that
obese rats had an increase in both Ang I and Ang II
concentrations when compared with control rats. Plasma levels
of Ang 1–7 were significantly lower in obese rats when compared
with control rats.
Vascular Responses to Angiotensin II and Norepinephrine
The internal diameter of resistance mesenteric arteries (obese
= 236.764.4, n = 34; control = 239.064.4, n= 39) as well as the
contractile response to KCl (force in mN, obese = 10.660.4;
control = 10.860.6) did not differ between obese and control rats.
Ang II induced concentration-dependent contraction in mes-
enteric arteries from both obese and control rats. However, in
preparations with intact endothelium from obese rats this response
was impaired in comparison with the respective preparation of
control rats. After endothelium removal, the response to Ang II
was similar in preparations from obese and control rats
(Figure 1A).
To determine whether the decreased vasoconstriction in obese
rats was specific to Ang II, vascular reactivity to an alternative
vasoconstrictor, NE, was examined. There were no differences in
the contractile responses to NE between control rats and obese in
preparations with or without endothelium (Figure 1B). Consider-
ing this, the studies were carried out with Ang II in endothelium-
intact mesenteric arteries.
Role of AT1 and AT2 Receptors on Angiotensin
II–Induced Contraction
To determine the contribution of the AT1 receptor activation
on Ang II effects in obese and control rats, vessels were pre-
exposed to the selective AT1 antagonist losartan (0.3 mM).
Incubation with losartan slightly reduced Ang II-induced contrac-
tile response in obese rats whereas it almost abolished this response
in control rats (Figure 2A). Higher concentrations of the AT1
antagonist (10 mM) abolished the responses to Ang II in both
groups.
We then examined whether AT2 receptor-mediated vasodila-
tation caused the impaired contraction to Ang II in mesenteric
arteries from obese rats using the AT2 receptor antagonist PD
123319. Pretreatment with this antagonist augmented the
responses to Ang II in preparations from both control and obese
rats. However, force development in response to this peptide
seems to be more dependent on AT2 receptors in preparations
from obese rats since the effect of the antagonist in these rats was
found to increase Ang II-elicited contraction at the three
concentrations tested restoring the impaired contraction back to
control levels, whereas in preparations from control rats only the
response evoked by lower concentration of Ang II was increased
by the antagonist (Figure 2B).
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Role of Nitric Oxide and Reactive Oxygen Species on
Angiotensin II–Induced Contraction
To investigate if the decreased response to Ang II in obese rats
was due to increased NO release from the endothelium;
concentration-response curves to Ang II were obtained in the
presence of the NOS inhibitor L-NAME. In the presence of L-
NAME, there was a similar increase in the efficacy of Ang II in
vessels from both control and obese rats. In addition, similarly to
the effects of endothelium removal, in the presence of L-NAME,
no differences between segments of control and obese rats were
observed, suggesting that the decreased response to Ang II in
obese rats was dependent on NO release from the endothelium
(Figure 3A).
Table 1. General characteristics of sixteen-week-old control and obese rats.
Parameter C MSG (n=10)
Body weight (g) 392.364.92 358.668.26 *
Naso-anal length (cm) 26.0260.29 23.4460.08 *
Lee index (x100) 28.5760.17 30.5060.25 *
Retroperitoneal WAT (g/100 g) 0.7860.05 2.7560.14 *
Periepididymal WAT (g/100 g) 0.6660.073 2.4160.16 *
Soleus muscle (g/100 g) 0.03560.002 0.03660.002
Extensor digitorum longus muscle (g/100 g) 0.03360.002 0.03160.002
Triacylglycerols (mg/dL) 68.5063.29 122.8066.48 *
Total colesterol (mg/dL) 65.2062.85 67.0063.33
HDL-colesterol (mg/dL) 15.4460.84 16.4461.55
LDL-colesterol (mg/dL) 35.162.44 45.564.2 *
VLDL-colesterol (mg/dL) 13.760.66 24.5461.29 *
Glucose (mg/dL) 97.163.49 93.962.69
Insulin (ng/mL) 13.760.97 25.662.52 *
HOMA-IR index 3.3160.29 6.2160.80 *
HOMA-b index 47.4663.63 92.8669.19 *
Angiotensin I (pg/mL) 32.9561.22 81.5465.10 *
Angiotensin II (pg/mL) 17.1962.48 48.7061.57 *
Angiotensin-(1–7) (pg/mL) 87.1468.08 55.0365.4 *
Blood Pressure (mmHg) 113.961.85 112.862.86
WAT, white adipose tissue; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; HOMA-IR, homeostasis model assessment-
insulin resistance; Values are mean 6 SEM. *P,0.05 vs. control. N = 7–10/group.
doi:10.1371/journal.pone.0106029.t001
Figure 1. Effect of obesity on contraction of mesenteric arteries to angiotensin II and norepinephrine. A- Non-cumulative
concentration–response curves to angiotensin II (ANG II) obtained in different segments of endothelium intact and endothelium denuded mesenteric
arteries from control and monosodium glutamate (MSG)-induced obese rats. The curves were performed on a top of a submaximal tone (30 to 40% of
the maximum response) induced by norepinephrine (NE). B- Cumulative concentration–response curves to NE in endothelium intact and
endothelium denuded mesenteric arteries from control and monosodium glutamate-induced obese rats. Each point represents the mean 6 SEM.
*, P,0.05 vs. Control; #, P,0.05 vs. respective group in the absence of endothelium. N = 5–6/group.
doi:10.1371/journal.pone.0106029.g001
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Since Ang II activates NAD(P)H oxidases in endothelial and in
vascular smooth muscle cells to produce ROS, which are involved
in Ang II-induced vascular effects, the participation of these
enzymes was assessed with apocynin, an inhibitor of NAD(P)H
oxidase. Apocynin reduced the response to Ang II in mesenteric
arteries from both obese and control rats. However, differently of
the observed with L-NAME, the decreased response to Ang II in
mesenteric arteries from obese rats was still observed after
apocynin incubation (Figure 3B).
Contribution of MAPKs on Angiotensin II-Induced
Contraction
Incubation of mesenteric arteries with PD98059, an ERK1/2
inhibitor, corrected the reduced Ang II-induced response in obese
without modifying the response to Ang II in control rats
(Figure 4A).
Inhibition of JNK (Figure 4B) or p38 MAPKs (Figure 4C) did
not modify the response to Ang II in control rats and reduced even
more the contractile response to Ang II in mesenteric arteries from
obese rats.
Western Blot Analysis of Vascular AT1 and AT2 Receptors
Western blot analysis demonstrated that the protein expression
of AT1 receptors in mesenteric arteries did not differ between
from control and obese rats (Figure 5A). AT2 receptors were
weakly expressed in mesenteric vessels control rats. However, in
vessels from obese rats, protein expression of AT2 receptors was
significantly increased (Figure 5B).
Effects of Angiotensin II on ERK 1/2 Phosphorylation in
Mesenteric Arteries
As shown in figure 6, similar basal expression of ERK1/2 was
found in vessels from control and obese rats. Ang II increased
ERK1/2 phosphorylation in both groups and the magnitude of
ERK1/2-induced phosphorylation was increased in mesenteric
arteries from obese rats compared with control preparations.
Figure 2. Contribution of angiotensin II receptors activation to the vascular effects of angiotensin. Mesenteric arteries with intact
endothelium from control and monosodium glutamate-induced obese rats were pretreated with the AT1 receptor antagonist losartan (0.3 and
10 mM) (A) or the AT2 receptor antagonist PD 123319 (1 mM) (B), for 30 min and non-cumulative concentration–response curves to angiotensin II
(ANG II) were obtained. Each point represents the mean 6 SEM. *, P,0.05 vs. Control. #, P,0.05 vs. respective group in the absence of blockade.
{, P,0.05 vs. Control + losartan. N = 5–6/group.
doi:10.1371/journal.pone.0106029.g002
Figure 3. Contribution of nitric oxide and NADPH oxidase to the vascular effects of angiotensin. Mesenteric arteries with intact
endothelium from control and monosodium glutamate-induced obese rats were pretreated with Nv-nitro-L-arginine methyl ester (L-NAME, 100 mM),
a nitric oxide synthase inhibitor (A) or apocynin (100 mM), a NADPH inhibitor (B) for 30 min and non-cumulative concentration–response curves to
angiotensin II (ANG II) were obtained. Each point represents the mean6 SEM. *, P,0.05 vs. Control. #, P,0.05 vs. respective group in the absence of
blockade. N = 6/group.
doi:10.1371/journal.pone.0106029.g003
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To investigate the specific role of AT1 and AT2 receptors
activation by Ang II on ERK1/2 phosphorylation, protein
expression of ERK1/2 was examined in mesenteric arteries
incubated with either losartan or PD123319 previously to the
incubation with Ang II. Blockade of either AT1 or AT2 receptor
attenuated ERK1/2 phosphorylation in mesenteric arteries from
both control rats and obese rats.
Effects of Angiotensin II on eNOS Phosphorylation in
Mesenteric Arteries
Phosphorylation of eNOS was increased in vessels from obese
rats compared to control rats in basal conditions. Stimulation with
Ang II failed to induce eNOS phosphorylation in mesenteric
arteries from both control and obese rats. Incubation of mesenteric
arteries with the ERK1/2 inhibitor (PD98059) before Ang II
stimulation increased eNOS phosphorylation in control rats,
whereas it significantly decreased the phosphorylation of this
enzyme in vessels from obese rats (Figure 7).
Discussion
Cellular mechanisms and signaling pathways involved in the
vascular dysfunction present in obesity are currently subjects of
intensive investigation. In the present study, we highlighted the
importance of AT2 receptors and MAPKs in the functional and
molecular processes underlying the changes of vascular reactivity
to Ang II in obesity. Major findings in the present study
demonstrate that although MAPKs do not constitute the main
mechanism involved in the vasoconstriction in control rats, these
proteins are differentially regulated by Ang II in resistance
mesenteric arteries from obese rats. While SAPK/JNK and
Figure 4. Involvement of MAPKs on angiotensin II-induced contraction. Mesenteric arteries with intact endothelium from control and
monosodium glutamate-induced obese rats were pretreated with PD 98059 (1 mM), a specific MEK/ERK1/2 inhibitor (A), SB-203580 (1 mM), a catalytic
inhibitor for p38 MAPK (B), or SP 600125 (1 mM), an inhibitor of JNK (C) for 30 min and non-cumulative concentration–response curves to angiotensin
II (ANG II) were obtained. Each point represents the mean 6 SEM. *, P,0.05 vs. Control. #, P,0.05 vs. respective group in the absence of blockade.
N = 6/group.
doi:10.1371/journal.pone.0106029.g004
Figure 5. Effect of obesity on angiotensin II receptors protein expression in mesenteric arteries. Panels show densitometric analysis of
the Western blots for AT1 and AT2 protein expression in endothelium intact mesenteric arteries from control and monosodium glutamate-induced
obese rats. In A and C, Western blots for AT1 and AT2 receptors, respectively. Results were normalized to a-actin expression and expressed as units of
change from the control. Data are expressed as mean 6 SEM. *, P,0.05 vs. Control. N = 5/group.
doi:10.1371/journal.pone.0106029.g005
Vascular Reactivity to Angiotensin II in Obesity
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p38MAPK pathways contribute to the maintenance of vasocon-
striction to Ang II via AT1 receptors, activation of ERK1/2-
eNOS pathway via AT2 receptors in the endothelium contributes
to counteracting contraction and decrease the response to Ang II
in obese rats.
In the present study, Ang II dose-dependently contracted small
arteries from control and obese rats. However, responsiveness in
vessels from obese rats was significantly lower than in control rats.
This alteration appears to be receptor specific, because contraction
induced by the adrenergic agonist NE was not affected in obese
animals. Underlying mechanisms for the changes in Ang II–
induced response in obese rats could be due to alterations in
systemic levels of this peptide. In fact, enhanced activity of the
RAS, represented by increased circulating angiotensinogen, renin,
aldosterone, and angiotensin-converting enzyme activity has been
reported in obesity [30–32]. Accordingly, an important finding in
the present study is that circulating concentrations of Ang I and
Ang II peptides were markedly increased in obese rats. Thus, the
reduced contractile response to Ang II in these animals could
represent a compensatory mechanism to counteract the increase in
the synthesis and/or release of components of local and systemic
RAS.
Since its discovery, the RAS has been considered an important
component of the disturbances in the cardiovascular system.
Several experimental data have demonstrated that Ang II is not
the only biologically active component of the tissue and circulating
RAS. Besides Ang II, several other angiotensin peptides have
biological activity and are critically involved in the regulation of
vascular function with important pathological implications.
Among these is Ang-(1–7), a heptapeptide formed from Ang I or
Ang II by either a carboxypeptidase called conversion enzyme or
by tissue endopeptidases [33]. Ang-(1–7) exerts vascular relaxing
actions mediated by activation of the proto-oncogene MAS
product, stimulating similar pathways as AT2 activated by Ang
II. The relaxing effect evoked by Ang-(1–7) results from both the
potentiation of the dilating effects of bradykinin and the inhibition
of angiotensin converting enzyme (ACE). Through these multiple
pathways, Ang-(1–7) is considered an important component of a
counter-regulatory axis within the RAS, comprised by ACE2/
Ang-(1–7)/Mas receptor, which constitutes an intrinsic mechanism
to induce vasoprotective actions by counter-regulating the ACE/
Ang II/AT1R axis [34]. Indeed, the heptapeptide Ang-(1–7) has
been described to have many beneficial effects in the vasculature
that modulate the cardiovascular risk in obesity [35–37].
Accordingly, our findings that plasma levels of this peptide were
decreased in obese rats point to a possible shift towards decreased
activity of the ACE2/Ang-(1–7)/Mas receptor axis and increased
ACE/Ang II/AT1R axis in mesenteric arteries as a causal
mechanism for vascular dysfunction in obesity.
Ang II effects are thought to be regulated by the balance of AT1
and AT2 receptors expression. The AT1 receptor serves as a
control point for regulating the ultimate effects of Ang II on its
target tissues. Acutely, increased levels of Ang II may induce an
increased activation of AT1 receptors; however, chronic exposure
to high levels of Ang II evokes down regulation of AT1 receptors
and/or upregulation of AT2 receptors [38,39]. In this study, we
Figure 6. Effects of angiotensin II on ERK 1/2 phosphorylation in mesenteric arteries. Panels show densitometric analysis of the Western
blots for ERK1/2 protein expression in endothelium intact mesenteric arteries from control and monosodium glutamate-induced obese rats. Vessels
from both groups were stimulated with ANG II (0.1 mmol/L) or vehicle for 10 min in the absence or in the presence of the AT1 receptor antagonist
losartan (0.3 mM, 30 min), the AT2 receptor antagonist PD 123319 (1 mM, 30 min) or the ERK1/2 inhibitor PD98059 (1 mM, 30 min) and the
phosphorylation of ERK 1/2 was examined. Total protein levels are shown as loading controls. Data are expressed as mean 6 SEM. *, P,0.05 vs.
Control. N = 5–6/group.
doi:10.1371/journal.pone.0106029.g006
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demonstrated that obesity is accompanied by abnormal AT2
receptor upregulation in endothelium-intact mesenteric arteries,
which most likely reduces Ang II-induced contraction even with
no significant change in AT1 receptors expression. Consistent with
our current findings, the upregulation of AT2 receptors and the
role of this receptor mediating a reduced response to Ang II have
been observed in other studies in the brush-border and basolateral
membranes in obese Zucker rat [40], in the mesenteric arteries of
young SHR [41], and in the thoracic aorta of SHR [42] and Goto-
Kakizaki rat [14], a model of spontaneous normotensive type 2
diabetes. In fact, results from our study demonstrated that the
selective AT2 receptor blocker PD123319 corrected the reduced
response to Ang II in obese rats. Taking the above findings
together, we speculate that in an early phase of obesity, AT2
receptor-mediated signaling pathways play a major role counter-
acting the effects of Ang II–mediated vasoconstriction as a
consequence of the increased plasma levels of this peptide and
the decreased levels of Ang-(1–7). Selective blockade of the AT1
subtype receptor with losartan antagonized the constrictor actions
of Ang II in control group whereas it slightly decreased this
response in obese rats. These data indicate that in control rats,
Ang II–induced vasoconstriction in resistance mesenteric arteries
is mediated exclusively via AT1 receptors, whereas in obese rats
Ang II effects are associated with AT1- and PD123319-sensitive
receptors, which may be AT2 receptors, as demonstrated by our
findings.
It is well known that the endothelium plays an important role as
a target of a variety of cardiovascular risk factors, including obesity
and hypertension. Considering that Ang II is shown to induce the
release of NO [43,44], a role of endothelium and endothelium-
derived NO on Ang II-induced vasoconstriction was determined
in the isolated mesenteric arteries from control and obese rats. It is
interesting to note that the endothelium removal or addition of L-
NAME, an NOS inhibitor, not only increased Ang II-induced
contraction per se in both control and obese rats, but made the
contractile response to Ang II in mesenteric arteries from obese
rats to be comparable to that of control rats. These findings lead us
to postulate that the increased AT2 receptors expression is
accompanied by eNOS upregulation in mesenteric arteries from
obese rats, which depresses Ang II-induced contraction due to
simultaneous stimulation of AT2 and eNOS. In fact, the
pharmacological findings are supported by molecular data, where
mesenteric arteries from obese rats displayed increased eNOS
phosphorylation, probably contributing to attenuate the contrac-
tile response to Ang II in obese rats.
Interestingly, although basal expression of phosphorylated
eNOS was augmented in vessels from obese rats, pretreatment
with Ang II did not induce further increase in the activation of this
enzyme, indicating that constitutively high enzymatic activity of
eNOS appears to increase basal production of NO in obese rats,
leading to attenuation of the vasoconstrictor effect of Ang II. In
fact, this is supported by our findings that pretreatment with the
ERK1/2 inhibitor restored the increased phosphorylation of
eNOS and more importantly, that Ang II evokes ERK1/2
activation via both AT1 and AT2 receptors (as demonstrated by
our western blotting studies, figure 5), indicating that the Ang II-
induced augmented activation of ERK1/2 in vessels from obese
leads to high enzymatic activity of eNOS.
Figure 7. Effect of angiotensin II on eNOS phosphorylation in mesenteric arteries. Panels show densitometric analysis of the Western blots
for eNOS protein expression in endothelium intact mesenteric arteries from control and monosodium glutamate-induced obese rats. Vessels from
both groups were stimulated with ANG II (0.1 mmol/L) or vehicle for 10 min in the absence or in the presence of the ERK1/2 inhibitor PD98059 (1 mM,
30 min) and the phosphorylation of eNOS was examined. Total protein levels are shown as loading controls. Data are expressed as mean 6 SEM.
*, P,0.05 vs. Control, #, P,0.05 vs. respective group in the presence of ANG II. N = 5–6/group.
doi:10.1371/journal.pone.0106029.g007
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We further probed the mechanisms leading to vascular
activation of eNOS by Ang II. The observation that ERK1/2
inhibition with PD98059 before Ang II stimulation decreased
eNOS phosphorylation in mesenteric arteries from obese rats
indicates that ERK1/2-mediated eNOS phosphorylation contrib-
utes to decrease the response to Ang II in obese rats. Ang II has
been shown to activate signaling cascades that activate MAPKs,
including ERK1/2, JNK, and p38MAPK, which are implicated in
VSMC differentiation, proliferation, migration, and fibrosis [4–6].
The ERK1/2 pathway is the best characterized of the MAPK
pathways. Recent data implicates ERK1/2 in Ang II-mediated
vascular smooth muscle contraction. Touyz et al. [45] showed that
in vascular smooth muscle cells from human peripheral arteries,
the ERK1/2 signaling cascade plays a role in Ca2+ pathways,
which ultimately cause cell contraction. Enhanced activation of
vascular ERK1/2 by Ang II has also been implicated in
hypertension [46,47]. Here we identify the ERK1/2 pathway as
a putative mechanism counteracting contraction and decreasing
the response to Ang II in obese rats. This is supported by our
findings that incubation of mesenteric arteries with PD98059, an
ERK 1/2 inhibitor, corrected the reduced response to Ang II in
mesenteric arteries from obese rats without modifying the response
to this peptide in control rats.
Additional evidence for a role of ERK1/2 mediating the
reduced response to Ang II in obese rats was provided by western
blotting experiments showing that Ang II-induced ERK1/2
phosphorylation is augmented in mesenteric arteries from obese
rats. Interestingly, incubation with the AT2 receptor antagonist
corrected the increased ERK1/2 phosphorylation in obese rats,
indicating a dependence of AT2 receptors on Ang II-induced
ERK 1/2 activation.
Besides activating ERK1/2, Ang II also stimulates JNK and
p38MAPK, which are amongst the family of stress-induced kinases
that influence cell survival, apoptosis, and differentiation. JNK and
p38MAPK have also become known as important mediators of
vascular contraction [48,49]. However, no studies have so far
attempted to investigate the role of JNK and p38 MAPK on Ang
II-induced vascular contraction in mesenteric resistance arteries
and their contribution to the changes of the vascular reactivity to
Ang II in obesity. The findings of the present study provide
evidence for a role of these MAPKs in vascular dysfunction in
obesity. This is supported by the observations that inhibition of
JNK and p38 MAPK further reduced the contractile response to
Ang II in mesenteric arteries from obese rats but did not modify
the Ang II-induced contraction in control rats. These results
indicate that while SAPK/JNK and p38MAPK is not involved in
contraction of mesenteric vessels from control rats, they contribute
to the maintenance of vasoconstriction to Ang II in obese rats.
An increasing body of evidence has implicated oxidative stress
in the vascular dysfunction present in insulin-resistant states,
including diabetes, hypertension, and atherosclerosis. In this
regard, the role of ROS production by NADPH oxidases in Ang
II signaling, as well as a role for ROS in the development of
different diseases in which Ang II is a central component has been
extensively studied. Ang II activates NAD(P)H oxidases in
endothelial cells and in vascular smooth muscle cells to produce
ROS, such as superoxide and hydrogen peroxide (H2O2), which
are involved in the pleiotrophic effects of Ang II [50]. The fact that
inhibition of O2
2 production by the NOX inhibitor apocynin,
decreases vascular reactivity to Ang II in both control and obese
rats, indicate that NOX-derived O2
2 is importantly involved in
the signaling pathways resulting in Ang II-induced vasoconstric-
tion in mesenteric arteries. However, it is not involved in the
changes of the vascular reactivity observed in obese rats.
Conclusions
Our results demonstrate that MAPKs activity is differentially
regulated by Ang II in resistance mesenteric arteries from obese
rats. While SAPK/JNK and p38MAPK pathways contribute to
the maintenance of vasoconstriction to Ang II, probably via AT1
receptors, activation of ERK1/2-eNOS pathway via AT2
receptors in the endothelium contributes to counteracting
contraction and decrease the response to Ang II. These findings
highlight the importance of local alterations in the RAS, rather
than systemic effects, in mediating changes of the vascular function
in obesity and also provide important information regarding the
vasoconstrictor effects of Ang II that may be involved in vascular
dysfunction associated with obesity.
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